MX2022015524A - Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. - Google Patents
Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.Info
- Publication number
- MX2022015524A MX2022015524A MX2022015524A MX2022015524A MX2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A MX 2022015524 A MX2022015524 A MX 2022015524A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- ureido
- propoxy
- trans
- acetic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035994P | 2020-06-08 | 2020-06-08 | |
| PCT/US2021/036082 WO2021252309A1 (en) | 2020-06-08 | 2021-06-07 | Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022015524A true MX2022015524A (es) | 2023-03-22 |
Family
ID=78846441
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022015524A MX2022015524A (es) | 2020-06-08 | 2021-06-07 | Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. |
| MX2026000786A MX2026000786A (es) | 2020-06-08 | 2022-12-06 | Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4- propoxiciclohexil)-ureido]-thiazol-5-ilsulfanil}acetico y usos de las mismas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2026000786A MX2026000786A (es) | 2020-06-08 | 2022-12-06 | Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4- propoxiciclohexil)-ureido]-thiazol-5-ilsulfanil}acetico y usos de las mismas |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4161639A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023530785A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230048501A (cg-RX-API-DMAC7.html) |
| CN (2) | CN116056760A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021289591A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3181665A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022015524A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021252309A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093025A1 (en) | 2018-06-12 | 2019-12-19 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| US12479808B2 (en) | 2020-06-08 | 2025-11-25 | Vtv Therapeutics Llc | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0506662B8 (pt) * | 2004-01-06 | 2021-05-25 | Novo Nordisk As | compostos ativadores de glucoquinase |
| PT2576524T (pt) * | 2010-05-26 | 2017-11-17 | Vtv Therapeutics Llc | Resumo |
| IN2014DN09554A (cg-RX-API-DMAC7.html) * | 2012-05-17 | 2015-07-17 | Transtech Pharma Llc | |
| CA2903433A1 (en) * | 2013-03-04 | 2014-09-12 | Vtv Therapeutics Llc | Stable glucokinase activator compositions |
| HK1213197A1 (zh) * | 2013-03-04 | 2016-06-30 | Vtv治疗有限责任公司 | 包括葡糖激酶活化劑的固體組合物及其製備和使用方法 |
| DK3556354T3 (da) * | 2016-12-15 | 2025-08-04 | Hua Medicine Shanghai Ltd | Oral fremstilling af en glucokinaseaktivator og fremgangsmåde til fremstilling deraf |
-
2021
- 2021-06-07 CA CA3181665A patent/CA3181665A1/en active Pending
- 2021-06-07 CN CN202180056233.1A patent/CN116056760A/zh active Pending
- 2021-06-07 WO PCT/US2021/036082 patent/WO2021252309A1/en not_active Ceased
- 2021-06-07 KR KR1020237000609A patent/KR20230048501A/ko active Pending
- 2021-06-07 EP EP21821691.9A patent/EP4161639A4/en active Pending
- 2021-06-07 JP JP2023519156A patent/JP2023530785A/ja active Pending
- 2021-06-07 MX MX2022015524A patent/MX2022015524A/es unknown
- 2021-06-07 CN CN202511373032.0A patent/CN121202809A/zh active Pending
- 2021-06-07 AU AU2021289591A patent/AU2021289591A1/en active Pending
-
2022
- 2022-12-06 MX MX2026000786A patent/MX2026000786A/es unknown
-
2026
- 2026-03-04 JP JP2026034319A patent/JP2026108667A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2026000786A (es) | 2026-03-02 |
| CN116056760A (zh) | 2023-05-02 |
| JP2026108667A (ja) | 2026-06-30 |
| US20230219910A1 (en) | 2023-07-13 |
| EP4161639A4 (en) | 2024-01-17 |
| AU2021289591A1 (en) | 2023-01-19 |
| CA3181665A1 (en) | 2021-12-16 |
| WO2021252309A1 (en) | 2021-12-16 |
| JP2023530785A (ja) | 2023-07-19 |
| EP4161639A1 (en) | 2023-04-12 |
| CN121202809A (zh) | 2025-12-26 |
| KR20230048501A (ko) | 2023-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2026000786A (es) | Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4- propoxiciclohexil)-ureido]-thiazol-5-ilsulfanil}acetico y usos de las mismas | |
| SA522433155B1 (ar) | مركبات ثلاثية الحلقة مستبدلة | |
| CO2022008243A2 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos | |
| MX2021010674A (es) | Compuestos triciclicos condensados utiles como agentes anticancerigenos. | |
| PE20241305A1 (es) | Analogos de amilina | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| BRPI0418245B8 (pt) | composto derivado de nitróxi de prostaglandina, processo para preparar dito composto, composição farmacêutica compreendendo dito composto e usos destes | |
| WO2020113213A3 (en) | Cyclic pantetheine derivatives and uses thereof | |
| AR032752A1 (es) | Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| PT97689A (pt) | Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida | |
| CO2021017435A2 (es) | Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida | |
| AR119479A1 (es) | Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer | |
| CO2023008949A2 (es) | Forma cristalina de tolebrutinib, método de preparación y uso de la misma | |
| HRP20180113T1 (hr) | Uporaba metformina u kombinaciji s aktivatorom glukokinaze i kompozicije koje sadrže metformin i aktivator glukokinaze | |
| DOP2025000146A (es) | Compuesto quimérico protac, método de preparación del mismo y uso del mismo | |
| PH12021552004A1 (en) | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| SE8400332D0 (sv) | Forening for anvendning som mellanprodukt vid framstellning av lekemedel | |
| EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
| JOP20220281A1 (ar) | مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| ES2038630T3 (es) | Un procedimiento para preparar un compuesto de acido fenoxiacetico. | |
| MX2026001663A (es) | Formulaciones farmaceuticas de agonistas de gpr119 y usos de estas |